Given the strong induction of type III IFNs in response to STING activation in cancer cell and immune cell co-cultures and within the TME in vivo, we speculated that type III IFNs might play a role in the antitumor activity of the tumor cell-directed STINGa ADCs. The gene discussed is STING1; the disease is neoplasm.